Nitric-oxide-mediated Relaxations in Salt-induced Hypertension: Effect of Chronic Beta1 -selective Receptor Blockade
Overview
Authors
Affiliations
Background: Nebivolol is a new beta1-selective adrenergic receptor antagonist with a direct vasorelaxant effect that involves activation of the l-arginine-nitric oxide (NO) pathway. Therefore, treatment with nebivolol may protect against endothelial injury in hypertension.
Objective: To investigate whether chronic selective beta1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol.
Methods: Dahl salt-sensitive rats were treated for 8 weeks with standard chow or chow containing 4% NaCl alone or in combination with nebivolol (10 mg/kg per day) or atenolol (100 mg/kg per day). Isometric tension was continuously recorded in isolated aorta and small mesenteric arteries. Constitutive NO synthase (cNOS) activity was determined by [3H]citrulline assay.
Results: Chronic salt administration increased systolic blood pressure by 38 +/- 5 mmHg in salt-treated rats as compared with that in control rats. Both nebivolol and atenolol prevented a salt-induced increase in pressure. cNOS activity was significantly decreased by a high-salt diet. The impairment of endothelium-dependent relaxations in response to acetylcholine in salt-treated rats was prevented only by nebivolol, in both large and small arteries. In contrast, the reduced endothelium-independent relaxations and contractions in response to sodium nitroprusside and endothelin-1, respectively, were restored by both drugs. Nebivolol, but not atenolol, restored cNOS activity.
Conclusions: Despite nebivolol and atenolol having the same blood-pressure-decreasing effect, only nebivolol was able to prevent endothelial dysfunction. This study demonstrates for the first time that the acute NO-mediated vasodilatory action of nebivolol is also present during chronic treatment. Hence, nebivolol might become a new therapeutic tool with which to exert vascular protective effects against end-organ damage in conditions associated with NO deficiency.
Belenichev I, Goncharov O, Bukhtiyarova N, Kuchkovskyi O, Ryzhenko V, Makyeyeva L Biomedicines. 2024; 12(9).
PMID: 39335471 PMC: 11428500. DOI: 10.3390/biomedicines12091957.
Elsherif N, Mohsen Al-Mahallawi A, Abdelkhalek A, Shamma R Pharmaceutics. 2021; 13(5).
PMID: 34064916 PMC: 8150897. DOI: 10.3390/pharmaceutics13050700.
Del Mauro J, Prince P, Plantamura Y, Allo M, Parola L, Fernandez Machulsky N Hypertens Res. 2021; 44(7):791-802.
PMID: 33612826 DOI: 10.1038/s41440-021-00630-4.
Cseplo P, Vamos Z, Ivic I, Torok O, Toth A, Koller A PLoS One. 2016; 11(10):e0164010.
PMID: 27716772 PMC: 5055296. DOI: 10.1371/journal.pone.0164010.
Changing standard chow diet promotes vascular NOS dysfunction in Dahl S rats.
Spradley F, Ho D, Kang K, Pollock D, Pollock J Am J Physiol Regul Integr Comp Physiol. 2011; 302(1):R150-8.
PMID: 22031779 PMC: 3349380. DOI: 10.1152/ajpregu.00482.2011.